Sarvnaz Sadrameli

PharmD, BCOP

Rotations

Cellular Therapy, Medical Oncology

Education

PharmD: University of Texas at Austin College of Pharmacy
PGY1: University of Illinois at Chicago
PGY2 Oncology: University of Wisconsin Hospitals and Clinics - Madison

Residency Training

Practice Interests

Cellular Therapy, GVHD Management, Optimizing Conditioning Regimens

Professional Affiliation

Hematology/Oncology Pharmacy Association (HOPA)

American Society for Transplantation and Cellular Therapy (ASTCT)

Recent Publications

Sadrameli S, Bringgold S, Dow-Hillgartner E. Tolerability Assessment of Tyrosine Kinase Inhibitors in Patients With Solid Tumor Malignancies and Hypoalbuminemia. Ann Pharmacother. https://doi.org/10.1177/10600280241284923
Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs. 2021;81(1):125-56.
Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM. Authors' Reply to Bonnet et al. "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update". Drugs. 2021;81(5):615-7.